Lyra Therapeutics
Lyra Therapeutics is a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). They focus on creating long-acting, targeted treatments to improve the quality of life for CRS patients, leveraging proprietary technology to deliver medicines directly to affected tissues with sustained effects from a single administration.
Industries
Nr. of Employees
medium (51-250)
Lyra Therapeutics
Patents
Implantable scaffolds for treatment of sinusitis and method of reducing inflammation
US-11654213-B2
View Details
Implantable scaffolds for treatment of sinusitis and method of reducing inflammation
US-11654213-B2
View DetailsProducts
Long‑acting bioabsorbable nasal implant for surgically‑naïve anatomy (clinical‑stage)
Bioabsorbable implantable matrix formulated to deliver an anti‑inflammatory steroid locally to sinonasal tissues for sustained symptom relief over months; developed for placement in patients without prior sinus surgery (advanced clinical stage).
Long‑acting bioabsorbable nasal implant for post‑surgical anatomy (clinical‑stage)
Bioresorbable implant engineered to expand/line enlarged nasal anatomy following prior sinus surgery, formulated to deliver sustained anti‑inflammatory therapy locally for months.
Long‑acting bioabsorbable nasal implant for surgically‑naïve anatomy (clinical‑stage)
Bioabsorbable implantable matrix formulated to deliver an anti‑inflammatory steroid locally to sinonasal tissues for sustained symptom relief over months; developed for placement in patients without prior sinus surgery (advanced clinical stage).
Long‑acting bioabsorbable nasal implant for post‑surgical anatomy (clinical‑stage)
Bioresorbable implant engineered to expand/line enlarged nasal anatomy following prior sinus surgery, formulated to deliver sustained anti‑inflammatory therapy locally for months.
Services
Design and execution of multi‑phase clinical trials (Phase 2 and Phase 3) to evaluate safety, efficacy, PK, and patient‑reported outcomes for implantable drug‑device therapeutics in chronic rhinosinusitis.
Materials selection, formulation integration, device engineering, and commercialization planning for implantable matrices designed to deliver sustained local therapy.
Design and execution of multi‑phase clinical trials (Phase 2 and Phase 3) to evaluate safety, efficacy, PK, and patient‑reported outcomes for implantable drug‑device therapeutics in chronic rhinosinusitis.
Materials selection, formulation integration, device engineering, and commercialization planning for implantable matrices designed to deliver sustained local therapy.
Expertise Areas
- Clinical trial management for implantable drug‑device candidates
- Drug‑device combination development
- Localized sustained drug delivery
- Biomaterials engineering for implantables
Key Technologies
- Bioabsorbable/bioresorbable implant matrices
- Controlled‑release drug‑eluting implants
- Localized steroid (anti‑inflammatory) delivery
- Pharmacokinetic (PK) analysis
News & Updates
Lyra Therapeutics announced positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 for CRS.
Lyra Therapeutics will present 52-week extension results for the ENLIGHTEN 1 study at COSM 2025.
Lyra Therapeutics announced positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 for CRS.
Lyra Therapeutics will present 52-week extension results for the ENLIGHTEN 1 study at COSM 2025.